White label – Pompe disease - ClinicalTrials.eu

Study on the Effects of GSK4004280 and GSK4011499 in Adults with HIV Infections

Not recruiting

2 1
Investigated Diseases:
- HIV infection
Investigated Drugs:
- Gsk4004280
- Gsk4011499
Study on the Safety and Effectiveness of Telisotuzumab Vedotin for Patients with Previously Treated c-Met Positive Non-Small Cell Lung Cancer

Not recruiting

2 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:
- Telisotuzumab Vedotin
+2
Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

Not recruiting

3 1 1 1
Investigated Diseases:
- Chronic lymphocytic leukaemia
Investigated Drugs:
+5
Study of ALE.C04 and Pembrolizumab for Adults with Recurrent or Metastatic Head and Neck Cancer

Not recruiting

2 1 1 1
Investigated Drugs:
- Ale.c04
- Pembrolizumab
Study on the Effect of Botulinum Toxin Type A and Physiological NaCl 0.9% in Patients with Piriformis Syndrome

Not recruiting

3 1 1
Investigated Diseases:
- Piriformis syndrome
Investigated Drugs:
- Botulinum Toxin Type A
Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Not recruiting

2 1 1 1
Investigated Drugs:
+1
Study on Dulaglutide for Preventing Diabetes in Patients with Metabolic Syndrome Awaiting Kidney Transplantation

Not recruiting

3 1 1 1
Investigated Diseases:
- Renal transplant
Investigated Drugs:
- Dulaglutide
Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

Not recruiting

1 1 1 1
Investigated Drugs:
Study on Dulaglutide for Preventing Diabetes in New Kidney Transplant Patients

Not recruiting

3 1 1 1
Investigated Diseases:
- Renal transplant
Investigated Drugs:
- Dulaglutide
Study on Vilobelimab and Drug Combination for Treating Ulcerative Pyoderma Gangrenosum in Adults

Not recruiting

3 1 1
Investigated Diseases:
- Pyoderma gangrenosum
Investigated Drugs:
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies